Fruquintinib plus chemo vs chemo for first-line advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a targeted therapy called fruquintinib (a type of anti-angiogenesis drug) to standard chemotherapy (paclitaxel and carboplatin) is more effective than chemotherapy alone for advanced or recurrent endometrial cancer that is not dMMR. If you haven't had prior systemic therapy for advanced disease and your tumor is pMMR, this could be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced (stage III or IV), recurrent, or metastatic and confirmed as pMMR by a lab test.
- You must not have received any prior drug therapy for advanced cancer (except if you had adjuvant chemo more than 6 months ago and the cancer came back).
- You need to be in generally good health (able to care for yourself, with adequate blood counts, liver and kidney function).
- You must not have had certain prior cancer treatments, like anti-VEGF drugs or immunotherapy.
- You cannot have active infections, major heart or blood vessel problems, or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests adding fruquintinib (a targeted drug that blocks blood vessel growth) to chemotherapy after surgery for HER2-negative stomach or gastroesophageal junction cancer. It is for patients whose tumor did not respond well to previous treatment before surgery.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.